Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

AIMS/INTRODUCTION: Incretin therapy is a common treatment for type 2 diabetes mellitus. We have previously reported an anti‐prostate cancer effect of glucagon‐like peptide‐1 receptor (GLP‐1R) agonist exendin‐4. The attenuation of cell proliferation in the prostate cancer cell line was dependent on G...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigeoka, Toru, Nomiyama, Takashi, Kawanami, Takako, Hamaguchi, Yuriko, Horikawa, Tsuyoshi, Tanaka, Tomoko, Irie, Shinichiro, Motonaga, Ryoko, Hamanoue, Nobuya, Tanabe, Makito, Nabeshima, Kazuki, Tanaka, Masatoshi, Yanase, Toshihiko, Kawanami, Daiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477521/
https://www.ncbi.nlm.nih.gov/pubmed/32146725
http://dx.doi.org/10.1111/jdi.13247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477521/
https://www.ncbi.nlm.nih.gov/pubmed/32146725
http://dx.doi.org/10.1111/jdi.13247

Ejemplares similares